Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 5
1989 2
1990 1
1992 4
1993 4
1994 3
1995 8
1996 5
1997 6
1998 6
1999 10
2000 10
2001 11
2002 15
2003 16
2004 21
2005 20
2006 17
2007 21
2008 16
2009 16
2010 17
2011 18
2012 17
2013 16
2014 34
2015 40
2016 29
2017 41
2018 43
2019 37
2020 52
2021 54
2022 38
2023 44
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

629 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for jules marker of
Your search for Jules Markenhof retrieved no results
Migraine: disease characterisation, biomarkers, and precision medicine.
Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL, Schulte LH, Hadjikhani N, Sinclair AJ, Ashina H, Schwedt TJ, Goadsby PJ. Ashina M, et al. Lancet. 2021 Apr 17;397(10283):1496-1504. doi: 10.1016/S0140-6736(20)32162-0. Epub 2021 Mar 25. Lancet. 2021. PMID: 33773610 Review.
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M. Ades F, et al. J Clin Oncol. 2014 Sep 1;32(25):2794-803. doi: 10.1200/JCO.2013.54.1870. Epub 2014 Jul 21. J Clin Oncol. 2014. PMID: 25049332 Review.
Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A. It also exhibits worse prognosis and has a distinct profile of response to hormone therapy and c …
Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, …
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer. Dieci MV, et al. Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Semin Cancer Biol. 2018. PMID: 29024776 Free article. Review.
TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. ...
TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, …
Retinoblastoma: From genes to patient care.
Bouchoucha Y, Matet A, Berger A, Carcaboso AM, Gerrish A, Moll A, Jenkinson H, Ketteler P, Dorsman JC, Chantada G, Beck-Popovic M, Munier F, Aerts I, Doz F, Golmard L; European Retinoblastoma Group EuRbG. Bouchoucha Y, et al. Eur J Med Genet. 2023 Jan;66(1):104674. doi: 10.1016/j.ejmg.2022.104674. Epub 2022 Dec 5. Eur J Med Genet. 2023. PMID: 36470558 Review.
This is expected to facilitate assessment of the constitutional status of RB1, to provide an early risk stratification using molecular prognostic markers, to follow the response to the treatment in longitudinal studies, and to predict the response to targeted therapies. .. …
This is expected to facilitate assessment of the constitutional status of RB1, to provide an early risk stratification using molecular progn …
Performance of serum marker panels for liver fibrosis in chronic hepatitis C.
Parkes J, Guha IN, Roderick P, Rosenberg W. Parkes J, et al. J Hepatol. 2006 Mar;44(3):462-74. doi: 10.1016/j.jhep.2005.10.019. Epub 2005 Nov 21. J Hepatol. 2006. PMID: 16427156 Review.
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is characterised by hepatic fibrosis, used as a proxy measure of prognosis. Liver biopsy is a flawed reference standard and serum markers of fibrosis offer an attractive alternative. METHODS: A systematic review was conducted to a …
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is characterised by hepatic fibrosis, used as a proxy measure of prognosis. Liver biopsy is a fla …
Is the persistence of an epiphyseal scar of the knee a reliable marker of biological age?
Faisant M, Rerolle C, Faber C, Dedouit F, Telmon N, Saint-Martin P. Faisant M, et al. Int J Legal Med. 2015 May;129(3):603-8. doi: 10.1007/s00414-014-1130-x. Epub 2014 Dec 5. Int J Legal Med. 2015. PMID: 25476542
Among the available tools for determining skeletal age, some authors have stated that the disappearance of epiphyseal scars could be a useful marker. The aim of the present study was to assess whether the presence of an epiphyseal scar on the knee, as seen on a plain X-ray …
Among the available tools for determining skeletal age, some authors have stated that the disappearance of epiphyseal scars could be a usefu …
Comparison of biomarker for diagnosis of nitrous oxide abuse: challenge of cobalamin metabolic parameters, a retrospective study.
Grzych G, Deheul S, Gernez E, Davion JB, Dobbelaere D, Carton L, Kim I, Guichard JC, Girot M, Humbert L, Bennis A, Joncquel M, Chieux V, Joly A, Nasserdine P, Trillot N, Douillard C, Pigny P, Tard C. Grzych G, et al. J Neurol. 2023 Apr;270(4):2237-2245. doi: 10.1007/s00415-023-11570-z. Epub 2023 Jan 24. J Neurol. 2023. PMID: 36690804
Serum or urine N(2)O assays could not be routinely performed. Hence, it is necessary to investigate other biological markers such as metabolic markers. We aimed here to challenge the three main biological markers used for the diagnosis of nitrous oxide abuse …
Serum or urine N(2)O assays could not be routinely performed. Hence, it is necessary to investigate other biological markers such as …
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Di Leo A, Isola J. Di Leo A, et al. Clin Breast Cancer. 2003 Aug;4(3):179-86. Clin Breast Cancer. 2003. PMID: 14499010 Review.
This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the efficacy of anthracyclines in patients with breast cancer. ...Despite these findings, however, the reported studies do not provide the proof …
This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the …
Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers.
Bohlok A, Richard F, Lucidi V, Asmar AE, Demetter P, Craciun L, Larsimont D, Hendlisz A, Van Laethem JL, Dirix L, Desmedt C, Vermeulen P, Donckier V. Bohlok A, et al. Front Oncol. 2023 Oct 27;13:1260880. doi: 10.3389/fonc.2023.1260880. eCollection 2023. Front Oncol. 2023. PMID: 37965465 Free PMC article.
Surgical resection can lead to prolonged survival in patients with isolated liver metastases (LM) from various primary cancers. However, there are currently no validated predictive markers to discriminate between these oligo/argometastatic patients, who will benefit from s …
Surgical resection can lead to prolonged survival in patients with isolated liver metastases (LM) from various primary cancers. However, the …
629 results